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TopiramateResults from a previously conducted global phase III study (PREVAIL; NCT01142193) demonstrate the safety and
efﬁcacy of once-daily USL255, Qudexy™ XR (topiramate) extended-release capsules, as adjunctive treatment of
drug-resistant partial-onset seizures (POSs). In this study, we report a post hoc analysis of PREVAIL data accord-
ing to patient level of treatment resistance (based upon the number of concomitant antiepileptic drugs [AEDs]
and lifetime AEDs) at baseline, with patients deﬁned as either having “highly” drug-resistant seizures (≥2 con-
current AEDs and ≥4 lifetime AEDs) or having “less” drug-resistant seizures (1 concurrent AED or b4 lifetime
AEDs) at baseline. For each subgroup,median percent reduction in POS frequency (primary endpoint), responder
rate, Clinical Global Impression of Change (CGI-C), and Quality of Life in Epilepsy— Problems (QOLIE-31-P) sur-
vey were assessed. Of 249 PREVAIL patients, 115 were classiﬁed as having highly drug-resistant seizures
(USL255: n = 52, placebo: n = 63), and 134 were classiﬁed as having less drug-resistant seizures (USL255:
n = 72, placebo: n = 62) at baseline. For the primary endpoint, USL255 resulted in signiﬁcantly better seizure
outcomes compared with placebo regardless of drug-resistant status (P= .004 and P= .040 for “highly” and
“less”, respectively). Responder rate was also signiﬁcantly improved in patients with highly drug-resistant
group (P = .023). The CGI-C scores indicated signiﬁcant improvement in both subgroups (P = .003 and P =
.013 for “highly” and “less”, respectively). On the QOLIE-31-P, a signiﬁcant improvement on the seizure worry
subscale for the group with less drug-resistant seizures was noted in USL255-treated patients compared with
placebo-treated patients (P = .003); the overall score and all other subscales were not signiﬁcantly different
for both subgroups. We conclude that USL255 led to signiﬁcant improvements across multiple outcomes com-
paredwith placebo, including in those classiﬁed as having highly drug-resistant seizures to prior treatment,mak-
ing it a valuable treatment option for patients with epilepsy.
© 2014 Upsher-Smith Laboratories, Inc. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Up to 40% of patients with epilepsy still have ongoing seizures de-
spite being on their initial antiepileptic drug (AED) treatment [1].
While some of these patients may ultimately achieve seizure control
through other AED monotherapy regimens or upon initiation ofool of Medicine, Adult Epilepsy
63110, USA. Tel.: +1 314 362
).
nc. Published by Elsevier In
.adjunctive AED therapy, approximately 30% of patients remain resistant
to currently available treatments currently available treatments [2].
The use of successive AEDs is associatedwith a reduced likelihood of
achieving seizure freedom, yet the addition of a newAEDhas resulted in
approximately one in six patients achieving long-term seizure remis-
sion, even when as many as ﬁve prior AEDs had proven ineffective [3].
Therefore, continued trials of different AEDs in patients with medically
drug-resistant epileptic seizures may result in signiﬁcant improvement
in seizure control.
Immediate-release topiramate (TPM-IR) administered twice daily is
a broad-spectrum, well-established AED with nearly 20 years of dem-
onstrated efﬁcacy in the adjunctive treatment of epilepsy [4]. USL255c. This is an open access article under the CC BY-NC-ND license
Fig. 1. Seizure reduction (A) and responder rate (B) by drug-resistant status.
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Laboratories, Inc., Maple Grove, MN) is a proprietary, once-daily formu-
lation developed to deliver consistent release over a 24-hour dosing in-
terval [5]. In phase I studies, USL255displayed equivalent drug exposure
to TPM-IR, with a smoother concentration–time curve and an
improved steady-state PK proﬁle (e.g., reduced ﬂuctuation index, sig-
niﬁcantly decreasedmaximumplasma concentrations) [6,7]. The recent
PREVAIL phase III study demonstrated that USL255 signiﬁcantly im-
proved seizure control in adults with drug-resistant partial-onset sei-
zures (POSs) taking one to three concomitant AEDs [8]. USL255 was
recently approved by the FDA (March 11, 2014) as initial monotherapy
in patients ≥10 years of age with POSs or primary generalized tonic–
clonic (PGTC) seizures and adjunctive therapy in patients ≥2 years of
age with POSs, PGTC seizures, or seizures associated with Lennox–
Gastaut syndrome [9].
The objective of this post hoc analysis of the PREVAIL study data was
to evaluate the efﬁcacy of USL255 in patients with the most drug-
resistant epilepsy. In addition, we report Clinical Global Impression of
Change (CGI-C) and quality-of-life ﬁndings in PREVAIL subgroups also
stratiﬁed by the level of AED treatment resistance.
2. Methods
2.1. Original PREVAIL study
Detailed methods of the original PREVAIL study (NCT01142193)
have been described previously [8]. Brieﬂy, PREVAIL was a randomized,
multinational, multicenter, double-blind, placebo-controlled, parallel-
group study of USL255. The study included an 8-week baseline phase,
a 3-week titration phase, and an 8-weekmaintenance phase. Themain-
tenance phase was followed by a 3-week down titration or entry into a
one-year open-label extension (OLE) study (NCT01191086). Eligible
patients were adults 18–75 years of age with a conﬁrmed diagnosis of
POSs (for≥1 year) with aminimumof eight POSs (with orwithout sec-
ondary generalization) and no more than 21 consecutive seizure-free
days during the 8-week baseline phase. Patients were required to
be on a stable regimen of one to three AEDs. Prior to randomization,
all patients provided written informed consent. Patients were ran-
domized 1:1 to once-daily USL255 or placebo, and titration occurred
in 50 mg/week increments over the 3-week titration phase to themain-
tenance dosage of 200 mg/day USL255 or matching placebo. Primary
and key secondary efﬁcacy endpoints were median percent reduction
from baseline in weekly POS frequency and responder rate (proportion
of patients with ≥50% reduction in seizure frequency) for the entire
treatment period (titration and maintenance phases). Clinical status
assessments included the CGI-C with assessments completed by inves-
tigators at the end of the maintenance phase or upon early discontinu-
ation. The CGI-C is a clinician-reported 7-point scale with lower scores
indicating greater improvement (scores range from 1= very much im-
proved to 7 = very much worse). The Quality of Life in Epilepsy —
Problems (QOLIE-31-P) survey was completed at the end of baseline
and at the end of maintenance by patients in countries where it was
available and validated for the spoken language. TheQOLIE-31-P is com-
posed of 7 subscales including seizureworry, overall quality of life, emo-
tions, energy, mental activity, medication effects, and daily activities.
Higher QOLIE-31-P scores indicate greater well-being.
2.2. Methods for this post hoc analysis
In the post hoc analyses described here, subgroupswere based upon
the baseline level of AED resistance using the number of current
concomitant AEDs and lifetime AEDs as a surrogate measure of drug re-
sistance. Speciﬁcally, patients were deﬁned as either having “highly”
drug-resistant seizures (≥2 concurrent AEDs and ≥4 lifetime AEDs)
or having “less” drug-resistant seizures (1 concurrent AED or b4 life-
time AEDs) based upon our clinical experience and a more stringentapproach relative to a recent analysis deﬁning “refractory” as those pa-
tients on 3 or more concomitant AEDs [10]. For each of these two sub-
groups, median percent reduction in POS frequency, responder rate,
CGI-C, and QOLIE-31-P were assessed. Differences between USL255
and placebo treatment groups were compared using a Wilcoxon rank-
sum test (median percent reduction in POS frequency) and Fisher's
exact test (responder rate). Treatment effect on the overall mean CGI-
C scores was assessed using an analysis of variance (ANOVA) model,
where the CGI-C score was the response variable and treatment and
geographic region were the ﬁxed effects. Quality of Life in Epilepsy —
Problems comparisons were based upon an analysis of covariance
(ANCOVA) model with the baseline score as the covariate. Analyses
were performed using the intent-to-treat (ITT) population (all patients
who received at least one dose of study drug and had at least one
evaluable postrandomization diary entry).
3. Results
Baseline demographics have been reported in detail for the full
patient population [8]. Brieﬂy, the overall population, on average,
reﬂected a patient populationwith difﬁcult-to-treat seizures. Themedi-
an duration of epilepsy was approximately 20 years, and 20% of the
patients had taken ≥7 lifetime AEDs. Most (76%) were on an AED regi-
men with at least two concomitant AEDs. Active treatment and
placebo groups were well matched with respect to baseline demo-
graphics and clinical characteristics. Of the 249 patients included in
the total ITT study population, 115 were classiﬁed in this post hoc anal-
ysis as having highly drug-resistant seizures (USL255: n = 52, placebo:
n = 63), and 134 were classiﬁed as having less drug-resistant seizures
(USL255: n = 72, placebo: n = 62) at baseline. Completion rates were
high and were similar between the group with highly drug-resistant
seizures and the group with less drug-resistant seizures (87.0% and
87.3%, respectively).
Seizure frequency (as assessed by median percent reduction in
POS frequency) was signiﬁcantly reduced in both the highly drug-resis-
tant and less drug-resistant subgroups (USL255: 40.4% versus placebo:
18.1%, P= .004 and USL255: 37.7% versus placebo: 22.7%, P= .040, re-
spectively; Fig. 1A). Responder rate was also signiﬁcantly improved in
patients with highly drug-resistant seizures (USL255: 38.5% versus pla-
cebo: 19.0%, P= .023; Fig. 1B). The responder rate observed in patients
with less drug-resistant seizures was numerically greater in the USL255
group compared with the placebo group but did not reach the level of
statistical signiﬁcance (USL255: 37.5% versus placebo: 27.4%, P= .269).
For both efﬁcacy outcomes, improvements with USL255 in the group
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with placebo (Fig. 1).
For the CGI-C, patients in both subgroups were signiﬁcantly im-
proved with USL255 compared with placebo (mean CGI-C score at the
end of maintenance = USL255: 3.1 versus placebo: 3.7, P = .003 and
USL255: 2.8 versus placebo: 3.2, P = .013 in the group with highly
drug-resistant seizures and in the group with less drug-resistant sei-
zures, respectively; Fig. 2). Three times as many patients with highly
drug-resistant seizures receiving USL255 (33.3%) had CGI-C scores
that were ‘very much improved’ or ‘much improved’ compared with
those receiving placebo (11.1%; P= .005). On the QOLIE-31-P, a signif-
icant improvement on the seizure worry subscale for the group with
less drug-resistant seizures was noted in USL255-treated patients com-
pared with placebo-treated patients (P= .003); the overall score and
all other subscales were not signiﬁcantly different for both subgroups.
4. Discussion
In this post hoc subgroup analysis of the PREVAIL study, USL255was
signiﬁcantlymore efﬁcacious than placebo regardless of a patient's level
of treatment resistance at baseline, deﬁned based upon both the num-
ber of concomitant AEDs and the number of lifetime AEDs. This is nota-
ble given that prior history of failure of AEDs to achieve adequate
seizure control is associated with a lower probability of response to a
newly administered treatment [3]. The current results are consistent
with the primary ﬁndings from the PREVAIL study, which demonstrated
that USL255 signiﬁcantly reduced median percent seizure frequency
and signiﬁcantly improved responder rate relative to placebo in the en-
tire patient population [8]. The current ﬁndings also are in line with a
post hoc analysis reported along with the primary PREVAIL ﬁndings in
which efﬁcacy was evaluated according to the number of baseline con-
comitant AEDs. In that analysis, patients taking the most concomitant
AEDs (≥3) showed signiﬁcantly greater seizure control with USL255
thanwith placebo as assessed by bothmedianpercent seizure reduction
(52.8% [n = 33] versus 11.4% [n = 38], P b .001) and responder rate
(57.6% versus 13.2%, P b .001) [8].
Optimal treatment of even the most drug-resistant patients is a pri-
ority, given the patient burden associated with inadequate seizure con-
trol both in terms of diminished quality of life and in terms of higher
morbidity and mortality [11–13]. Annual total costs of drug-resistant
epilepsy in the United States approach $4 billion, with average annual
health-care costs for a patient with drug-resistant seizures (deﬁned as
those on≥3 AEDs) at $33,613 [10]. Patient beneﬁt in the current analy-
ses was evident not only through traditional measures of seizure fre-
quency but also on the CGI-C, which indicated that clinicians deemed
patient status signiﬁcantly improved with USL255 relative to placebo.
On the QOLIE-31-P, only the seizure worry subscale for the group
deemed having less drug-resistant seizures showed a signiﬁcant differ-
ence comparedwith placebo, though a lack of signiﬁcance onQOLIE-31-
P subscales such as overall quality of life may not be surprising, givenFig. 2.Mean CGI-C scorea at the end of the maintenance phase by drug-resistant status.
aLower scores indicate greater improvement.the relatively short duration of the study. Because commonly reported
adverse events with AEDs such as TPM-IR include fatigue and cognitive
effects [14], the lack of signiﬁcance on subscales for energy, mental ac-
tivities, and medication effects is notable in that USL255 was compara-
ble with placebo.
The authors acknowledge that the assumptions used in this post hoc
analysis include a distinct and author-deﬁned threshold for “highly” and
“less” drug-resistant seizures. A task force appointed by the Internation-
al League Against Epilepsy has proposed a deﬁnition of “refractory” or
“drug-resistant” epilepsy as a failure of adequate trials of two, tolerated,
appropriately chosen, and administered AEDs (as either monotherapy
or adjunctive therapy) [15]. Our study design allows clear deﬁnition of
seizure frequency among our study groups but does not allow deﬁnitive
veriﬁcation of adequate trials of past AEDs. Lack of deﬁnitive veriﬁcation
of adequate AED trials is a limitation of the study. In spite of this limita-
tion, the goal of this analysis was to isolate patients with themost drug-
resistant seizures froma group already establishedwith a priori-deﬁned
criteria that existedwithin the strict parameters of a clinical studywhile
still allowing for a comparison of similarly sized groups.
The speciﬁc deﬁnitions we chose for patients having “highly drug-
resistant” seizures (≥2 concurrent AEDs and ≥4 lifetime AEDs) or pa-
tients having “less drug-resistant” seizures (1 concurrent AED or b4 life-
time AEDs) were based on our clinical experience as well as a recent
pharmacoeconomic study that classiﬁed 'refractory patients' as those
on 3 or more AEDs [10]. Our analysis investigates an important group
of patientswith ILAE-deﬁned “treatment failure.” The importance of on-
going investigation of patients deﬁned as having “treatment failure” in-
cludes past studies showing that their seizures patients can improve
with further treatment even after their seizures fail to improve with
two to ﬁve AEDs [3]. If complete seizure control is not achievedwith tri-
als of two appropriate AEDs, the likelihood of success with subsequent
regimens is much reduced [16], necessitating a careful clinical reevalu-
ation of the etiology of seizures and exploration of other treatment op-
tions, such as epilepsy surgery. However, drug resistance may “remit”
over time (at a rate of 4% per year among adults and a higher rate
among children), suggesting a ﬂuctuating course in seizure response
[16]. Additionally, other studies provide a quantitative estimate of the
value of changing drug therapy in patients in whom seizures were un-
controlled by previous therapy [17]. Our results help to conﬁrm the
principle that intractable seizures may respond to ongoing treatment
with different AEDs. It should be noted that the PREVAIL study was
not powered to detect differences in the subgroups examined in this
post hoc analysis. To our knowledge, this is the ﬁrst analysis to deﬁne
drug-resistant status based on both lifetime AED use and concomitant
AED use.
5. Conclusion
USL255 resulted in signiﬁcant improvement for the primary end-
point, compared with placebo, regardless of a patient's level of drug re-
sistance at baseline. Responder rate was also signiﬁcantly improved in
patients with highly drug-resistant seizures. The CGI-C scores indicated
signiﬁcant improvement at study end in both subgroups, and USL255
was not associated with negative effects relative to placebo on QOLIE-
31-P subscales for energy, mental activities, and medication effects. In
this post hoc analysis, USL255 efﬁcacy was signiﬁcantly improved rela-
tive to placebo, even in those patients likely to be highly resistant to
treatment making it a valuable treatment option for patients with
epilepsy.
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